What You Should Know
- The Shift: Wheel’s 2026 report, based on 1.4 million visits, reveals that the “land grab” phase of virtual care is over. Growth is no longer driven by first-time visits but by continuity. 69% of all visits on the platform now come from returning users.
- The Engine: Women’s health has emerged as the dominant growth engine, accounting for nearly half of all visits. Specifically, midlife care (perimenopause/menopause) is a critical gap that is driving high-frequency return behavior.
- The Connector: Weight management (GLP-1s) has evolved from a transactional “prescription mill” into a systemic entry point. These programs are acting as the “infrastructure” for broader chronic care, pulling patients into long-term metabolic and hormonal health pathways.
The 69% Tipping Point
The most striking finding in the data is the flip in user behavior. In the early days of telehealth, most volume came from new users seeking one-off urgent care. Today, 69% of visits on the Wheel platform come from returning users.
This signals a maturation of the market. Patients aren’t just using virtual care as a backup option; they are treating it as their primary “medical home” for specific conditions. For digital health companies, this means the path to profitability isn’t buying more Facebook ads; it is building “longitudinal infrastructure” that keeps the patient coming back.
The Women’s Health Powerhouse
If retention is the goal, Women’s Health is the vehicle. The category now accounts for nearly half of all visits on the platform. Crucially, the data highlights a “missing middle” in the market: midlife and perimenopause care. While younger demographics drive volume in birth control and urgent care, midlife women are returning at higher rates, signaling a massive unmet demand for complex, hormonal health management.
“Women continue to drive the majority of virtual care visits,” the report notes. “Midlife women, in particular, are… signaling unmet demand in menopause.”
GLP-1s: From Transaction to Infrastructure
The report also reframes the narrative around weight management. For the past two years, the industry has been obsessed with the explosion of GLP-1 drugs (like Ozempic and Wegovy). Critics feared these programs were just “pill mills.”
Wheel’s data suggests otherwise. Weight management has become a “systemic connector.” Patients who enter through the “front door” of a GLP-1 program are often progressing into multi-condition care, addressing metabolic, hormonal, and chronic needs.
These programs are no longer just about the drug; they are about the “wrap-around services”—labs, education, and monitoring—that support retention. Programs that integrate these elements are significantly outperforming one-off services on both engagement and outcomes.
The 2026 Playbook
The implications for clinical and product leaders are clear: Stop building for the first visit. The winners in 2026 will be the companies that can transition a patient from an episodic “entry point” (like a UTI or a weight loss consult) into a sustained, longitudinal relationship. As the report concludes, “The organizations that succeed are those that treat virtual care as a foundation for ongoing relationships.”
